scispace - formally typeset
Journal ArticleDOI

Standardizing training for Pressurized Intraperitoneal Aerosol Chemotherapy.

TLDR
An international panel of PIPAC experts created by means of a consensus meeting a structured 2-day training course including essential theoretical content and practical exercises enabling participants to safely implement PIPac.
Abstract
Background PIPAC is a novel mode of intraperitoneal drug delivery for patients with peritoneal cancer (PC). PIPAC is a safe treatment with promising oncological results. Therefore, a structured training program is needed to maintain high standards and to guarantee safe implementation. Methods An international panel of PIPAC experts created by means of a consensus meeting a structured 2-day training course including essential theoretical content and practical exercises. For every module, learning objectives were defined and structured presentations were elaborated. This structured PIPAC training program was then tested in five courses. Results The panel consisted of 12 experts from 11 different centres totalling a cumulative experience of 23 PIPAC courses and 1880 PIPAC procedures. The final program was approved by all members of the panel and includes 12 theoretical units (45 min each) and 6 practical units including dry-lab and live surgeries. The panel finalized and approved 21 structured presentations including the latest evidence on PIPAC and covering all mandatory topics. These were organized in 8 modules with clear learning objectives to be tested by 12 multiple-choice questions. Lastly, a structured quantifiable (Likert scale 1–5) course evaluation was created. The new course was successfully tested in five courses with 85 participants. Mean overall satisfaction with the content was rated at 4.79 (±0.5) with at 4.71 (±0.5) and at 4.61 (±0.7), respectively for course length and the balance between theory and practice. Conclusions The proposed PIPAC training program contains essential theoretical background and practical training enabling the participants to safely implement PIPAC.

read more

Citations
More filters
Journal ArticleDOI

Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?

Olivia Sgarbura, +62 more
- 01 Jan 2021 - 
TL;DR: Homogeneous treatment standards of new techniques are important to guarantee safe implementation and practice but also to allow comparison between cohorts and multi-center analysis of merged data including registries.
Journal ArticleDOI

Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC).

TL;DR: In patients with unresectable colorectal peritoneal metastases undergoing PIPAC-OX monotherapy, some major adverse events occurred and minor adverse events were common, and the clinical relevance of observed biochemical, pathological, and ascites responses remains to be determined.
Posted ContentDOI

Effect of Pressurized Intraperitoneal Aerosol Chemotherapy on the Survival Rate of Patients with Peritoneal Carcinomatosis of Gastric Origin.

TL;DR: The overall survival at 6 months after the diagnosis of carcinomatosis was significantly better for PIPAC_CHEM patients and this difference appears to continue until at least 18 months.
Journal ArticleDOI

PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial.

TL;DR: In this article, the authors present the design and implementation of the first phase 1 trial to evaluate the safety and efficacy of PIPAC in the United States, which is an ongoing prospective phase 1 clinical trial for patients who have histologically confirmed ovarian, uterine, gastric, appendiceal, or colorectal cancer with metastases.
References
More filters
Journal ArticleDOI

No surgical innovation without evaluation: the IDEAL recommendations.

TL;DR: Recommendations for the assessment of surgery based on a five-stage description of the surgical development process are proposed and the widespread use of prospective databases and registries are encouraged.
Journal ArticleDOI

Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy.

TL;DR: PIPAC shows superior pharmacological properties with high local concentration and low systemic exposure, and can induce regression of PC in chemoresistant tumors, using 10 % of a usual systemic dose.
Journal ArticleDOI

Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications

TL;DR: From the findings, PIPAC has been shown to be feasible and safe and can be considered as a treatment option for refractory, isolated peritoneal metastasis of various origins, however, its use in further indications needs to be validated by prospective studies.
Journal ArticleDOI

Description of a novel approach for intraperitoneal drug delivery and the related device

TL;DR: This device and the related approach significantly improve both distribution and penetration of a test substance into the peritoneal cavity in a large animal model, which might be a significant progress in treating intraperitoneal disease, in particularPeritoneal carcinomatosis.
Journal ArticleDOI

Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States

TL;DR: This recommendation on a standardized delivery of HIPEC in patients with colorectal cancer represents an important first step in enhancing research in this field and studies directed at maximizing the efficacy of each of the key elements will need to follow.
Related Papers (5)